摘要
免疫治疗已经改变了晚期非小细胞肺癌(NSCLC)的治疗格局,在一线及后线治疗中均显现出巨大潜能。同时,随着免疫治疗的广泛应用,仍有许多问题需要进一步探讨,如疗效预测生物标志物的探索、免疫治疗模式的优化、免疫相关不良反应和特殊人群的管理等。本综述梳理了晚期NSCLC免疫治疗的研究进展,并探讨了面临的挑战和未来发展方向。
Immunotherapy has changed the treatment landscape of advanced non-small cell lung cancer(NSCLC),showing great potential in the treatment of untreated and relapsed or refractory(R/R)patients.However,numerous issues that need further exploration remain with the wide application of immunotherapy.They include the exploration of biomarkers for efficacy prediction,the optimization of immunotherapy modalities,immune-related adverse effects,and the management of special populations.This review summarizes the progress of the research on immunotherapy for advanced NSCLC and discusses its challenges and future directions.
作者
王婧怡
钟雨玲
邬麟
WANG Jingyi;ZHONG Yuling;WU Lin(The Second Department of Thoracic Oncology,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China;Graduate Collaborative Training Base of Hunan Cancer Hospital,University of South China,Hengyang Medical School,Hengyang 421001,China)
出处
《肿瘤防治研究》
CAS
2024年第6期409-418,共10页
Cancer Research on Prevention and Treatment
基金
湖南省科技创新计划(2023SK4024、2021SK51121)
湖南省肿瘤医院“科研攀登计划”(2X2020005-5)
北京市希思科临床肿瘤学研究基金会(Y-2019Genecast-024)。
关键词
非小细胞肺癌
免疫治疗
免疫检查点抑制剂
Non-small cell lung cancer
Immunotherapy
Immune checkpoint inhibitors
